Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth

Hanne Trap Wolf; Tine Brink Henriksen; Mads Langager Larsen; Anja Pinborg; Hanne Kristine Hegaard; Jesper Sune Brok; Lene Drasbek Huusom

Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth

Hanne Trap Wolf, Tine Brink Henriksen, Mads Langager Larsen, Anja Pinborg, Hanne Kristine Hegaard, Jesper Sune Brok, Lene Drasbek Huusom

1 Citationer (Scopus)

Abstract

Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.

Originalsprog	Engelsk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	182
Udgave nummer	47
ISSN	0041-5782
Status	Udgivet - 16 nov. 2020

Emneord

Cerebral Palsy/prevention & control
Child
Female
Humans
Infant, Newborn
Magnesium Sulfate/therapeutic use
Neuroprotection
Neuroprotective Agents/therapeutic use
Pregnancy
Premature Birth/prevention & control
Prenatal Care
Randomized Controlled Trials as Topic

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{03d5a8d96e0e4bf1bbc3369aaec3cd2b,

title = "Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth",

abstract = "Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.",

keywords = "Cerebral Palsy/prevention \& control, Child, Female, Humans, Infant, Newborn, Magnesium Sulfate/therapeutic use, Neuroprotection, Neuroprotective Agents/therapeutic use, Pregnancy, Premature Birth/prevention \& control, Prenatal Care, Randomized Controlled Trials as Topic",

author = "Wolf, \{Hanne Trap\} and Henriksen, \{Tine Brink\} and Larsen, \{Mads Langager\} and Anja Pinborg and Hegaard, \{Hanne Kristine\} and Brok, \{Jesper Sune\} and Huusom, \{Lene Drasbek\}",

year = "2020",

month = nov,

day = "16",

language = "English",

volume = "182",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "47",

}

TY - JOUR

T1 - Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth

AU - Wolf, Hanne Trap

AU - Henriksen, Tine Brink

AU - Larsen, Mads Langager

AU - Pinborg, Anja

AU - Hegaard, Hanne Kristine

AU - Brok, Jesper Sune

AU - Huusom, Lene Drasbek

PY - 2020/11/16

Y1 - 2020/11/16

N2 - Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.

AB - Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.

KW - Cerebral Palsy/prevention & control

KW - Child

KW - Female

KW - Humans

KW - Infant, Newborn

KW - Magnesium Sulfate/therapeutic use

KW - Neuroprotection

KW - Neuroprotective Agents/therapeutic use

KW - Pregnancy

KW - Premature Birth/prevention & control

KW - Prenatal Care

KW - Randomized Controlled Trials as Topic

UR - https://www.scopus.com/pages/publications/85096458792

M3 - Journal article

C2 - 33215580

SN - 0041-5782

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 47

ER -

Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth

Abstract

Emneord

Andre filer og links

Fingeraftryk

Citationsformater